Coreline Soft Clears Japan’s PMDA Hurdle, Accelerating Push into Key Asian Medical Device Market
Coreline Soft, a medical imaging artificial intelligence company, has cleared a major regulatory hurdle in Japan, laying another foundation for its global expansion.Japan is widely regarded as a challenging market for overseas medical AI companies, with its medical device approval process assessing
Coreline Soft, a medical imaging artificial intelligence firm, has successfully cleared Japan's PMDA regulatory hurdle, bolstering its global expansion plans. Japan is notorious for being a challenging market for overseas medical AI companies, as its approval process scrutinizes not only product performance but also clinical use, quality management systems, and local healthcare environment suitability.
The approval signifies Coreline Soft's ability to adapt and commercialize its AI technology across diverse healthcare and regulatory contexts, and Japan's high CT scanner density, coupled with an aging population and increased radiologist workload, presents significant potential for medical imaging AI. Coreline Soft's AVIEW Lung Nodule CAD, the first Korean-developed CT-based lung nodule CAD product in Japan, received approval after a rigorous review process encompassing clinical performance, real-world use, software reliability, and safety.
The approval allows Coreline Soft to offer its lung nodule detection CAD to new medical institutions in Japan and expand commercialization activities. The company has already established a commercial presence in Japan, with an increase in hospital customers in recent months, and can now introduce its own approved products through existing commercial infrastructure.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
